Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Prostate Cancer

Free Subscription 11.03.2019 1 Am J Clin Oncol 2 Anticancer Res 2 BMC Cancer 1 Br J Cancer 2 Br J Radiol 1 Clin Imaging 1 Endocrinology 1 Eur Radiol 8 Eur Urol 2 Int J Cancer 1 Int J Oncol 1 Int J Radiat Oncol Biol Phys 1 Int J Urol 1 J Nucl Med 10 J Urol 1 PLoS Genet 1 PLoS One 4 Prostate 1 Radiology

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Am J Clin Oncol

1. DEN RB, George D, Pieczonka C, McNamara M, et al
   Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer: Practical Management Issues for Patient Selection.
   Am J Clin Oncol. 2019 Mar 4. doi: 10.1097/COC.0000000000000528.
   PubMed     Text format     Abstract available
   
   

   
   Anticancer Res

2. PEPE P, Pennisi M
   Prostate Cancer Diagnosis and Management Across Twenty Years of Clinical Practice: A Single-center Experience on 2,500 Cases.
   Anticancer Res. 2019;39:1397-1401.
   PubMed     Text format     Abstract available
   
   
3. MIYAKE H, Matsushita Y, Watanabe H, Tamura K, et al
   Prognostic Significance of Time to Castration Resistance in Patients With Metastatic Castration-sensitive Prostate Cancer.
   Anticancer Res. 2019;39:1391-1396.
   PubMed     Text format     Abstract available
   
   

   
   BMC Cancer

4. ALVAREZ CS, Villamor E, Meza R, Rozek LS, et al
   Differences in prostate tumor characteristics and survival among religious groups in Songkhla, Thailand.
   BMC Cancer. 2018;18:1175.
   PubMed     Text format     Abstract available
   
   
5. SCHROEDER C, Grell J, Hube-Magg C, Kluth M, et al
   Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer.
   BMC Cancer. 2019;19:193.
   PubMed     Text format     Abstract available
   
   

   
   Br J Cancer

6. MIJUSKOVIC M, Saunders EJ, Leongamornlert DA, Wakerell S, et al
   Correction: Rare germline variants in DNA repair genes and the angiogenesis pathway predispose prostate cancer patients to develop metastatic disease.
   Br J Cancer. 2019 Mar 6. pii: 10.1038/s41416-019-0419.
   PubMed     Text format     Abstract available
   
   

   
   Br J Radiol

7. PIERRE DE M, Roberto Luigi C, Julien G, Thibault T, et al
   Percutaneous MR-guided whole-gland prostate cancer cryoablation: safety considerations and oncologic results in 30 consecutive patients.
   Br J Radiol. 2019 Mar 8. doi: 10.1259/bjr.20180965.
   PubMed     Text format     Abstract available
   
   
8. PATHMANATHAN AU, McNair HA, Schmidt MA, Brand DH, et al
   Comparison of prostate delineation on multimodality imaging for MR-guided radiotherapy.
   Br J Radiol. 2019 Jan 24:20180948. doi: 10.1259/bjr.20180948.
   PubMed     Text format     Abstract available
   
   

   
   Clin Imaging

9. HWANG SI, Lee HJ, Lee SE, Hong SK, et al
   Value of MR-US fusion in guidance of repeated prostate biopsy in men with PSA<10ng/mL.
   Clin Imaging. 2019;53:1-5.
   PubMed     Text format     Abstract available
   
   

   
   Endocrinology

10. GHINEA N
    Vascular Endothelial FSH Receptor, a Target of Interest for Cancer Therapy.
    Endocrinology. 2018;159:3268-3274.
    PubMed     Text format     Abstract available
    
    

    
    Eur Radiol

11. PURYSKO AS, Magi-Galluzzi C, Mian OY, Sittenfeld S, et al
    Correlation between MRI phenotypes and a genomic classifier of prostate cancer: preliminary findings.
    Eur Radiol. 2019 Mar 7. pii: 10.1007/s00330-019-06114.
    PubMed     Text format     Abstract available
    
    

    
    Eur Urol

12. AHMADZADEHFAR H, Essler M
    Prostate-specific Membrane Antigen Imaging: A Game Changer in Prostate Cancer Diagnosis and Therapy Planning.
    Eur Urol. 2019 Mar 1. pii: S0302-2838(19)30175.
    PubMed     Text format    
    
    
13. KARNES RJ, Motterle G
    Re: Evaluation of Cancer Specific Mortality with Surgery versus Radiation as Primary Therapy for Localized High Grade Prostate Cancer in Men Younger than 60 Years.
    Eur Urol. 2019 Feb 28. pii: S0302-2838(19)30168.
    PubMed     Text format    
    
    
14. DARCEY E, Pereira G, Salter A, Fritschi L, et al
    The Impact of Lifestyle-related Factors on Survival After a Prostate Cancer Diagnosis.
    Eur Urol. 2019 Feb 27. pii: S0302-2838(19)30151.
    PubMed     Text format    
    
    
15. OGAYA-PINIES G, Kadakia Y, Palayapalayam-Ganapathi H, Woodlief T, et al
    Use of Scaffolding Tissue Biografts To Bolster Vesicourethral Anastomosis During Salvage Robot-assisted Prostatectomy Reduces Leak Rates and Catheter Times.
    Eur Urol. 2018;74:92-98.
    PubMed     Text format     Abstract available
    
    
16. GANDAGLIA G, Bravi CA, Dell'Oglio P, Mazzone E, et al
    The Impact of Implementation of the European Association of Urology Guidelines Panel Recommendations on Reporting and Grading Complications on Perioperative Outcomes after Robot-assisted Radical Prostatectomy.
    Eur Urol. 2018;74:4-7.
    PubMed     Text format     Abstract available
    
    
17. HUGOSSON J, Roobol MJ, Mansson M, Tammela TLJ, et al
    A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.
    Eur Urol. 2019 Feb 26. pii: S0302-2838(19)30150.
    PubMed     Text format     Abstract available
    
    
18. HOFER L, Hohenfellner M
    Re: Radical Prostatectomy or Watchful Waiting in Prostate Cancer-29-Year Follow-up.
    Eur Urol. 2019 Feb 27. pii: S0302-2838(19)30164.
    PubMed     Text format    
    
    
19. BURDETT S, Boeve LM, Ingleby FC, Fisher DJ, et al
    Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis.
    Eur Urol. 2019 Feb 27. pii: S0302-2838(19)30111.
    PubMed     Text format     Abstract available
    
    

    
    Int J Cancer

20. SROUR B, Plancoulaine S, Andreeva VA, Fassier P, et al
    Circadian nutritional behaviours and cancer risk: New insights from the NutriNet-sante prospective cohort study: Disclaimers.
    Int J Cancer. 2018;143:2369-2379.
    PubMed     Text format     Abstract available
    
    
21. SUGAWARA T, Baumgart SJ, Nevedomskaya E, Reichert K, et al
    Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models.
    Int J Cancer. 2019 Mar 3. doi: 10.1002/ijc.32242.
    PubMed     Text format     Abstract available
    
    

    
    Int J Oncol

22. HUANG ZG, He RQ, Mo ZN
    Prognostic value and potential function of splicing events in prostate adenocarcinoma.
    Int J Oncol. 2018;53:2473-2487.
    PubMed     Text format     Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

23. D'AGOSTINO GR, di Brina L, Mancosu P, Franzese C, et al
    Re-Irradiation of Locally Recurrent Prostate Cancer with Volumetric Modulated Arc Therapy (Vmat).
    Int J Radiat Oncol Biol Phys. 2019 Feb 27. pii: S0360-3016(19)30285.
    PubMed     Text format     Abstract available
    
    

    
    Int J Urol

24. KOBAYASHI T
    Editorial Comment to Micro-ribonucleic acid expression signature of metastatic castration-resistant prostate cancer: regulation of NCAPH by antitumor miR-199a/b-3p.
    Int J Urol. 2019 Mar 4. doi: 10.1111/iju.13919.
    PubMed     Text format    
    
    

    
    J Nucl Med

25. HICKS RJ
    The Injustice of Being Judged by the Errors of Others: The Tragic Tale of the Battle for PET Reimbursement.
    J Nucl Med. 2018;59:418-420.
    PubMed     Text format    
    
    

    
    J Urol

26. SCIALPI M, D'Andrea A, Aisa MC, Malaspina CM, et al
    Re: Risk Stratification of Equivocal Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate: T. Ullrich, M. Quentin, C. Arsov, A. K. Schmaltz, A. Tschischka, N. Laqua, A. Hiester, D. Blondin, R. Rabenalt, P. Albers, G. Antoch and L. Sch
    J Urol. 2018;200:202-204.
    PubMed     Text format    
    
    
27. BAYNE CE
    Re: Missed Opportunities to Decrease Radiation Exposure in Children with Renal Trauma: T. W. Gaither, M. A. Awad, N. V. Leva, G. P. Murphy, B. N. Breyer and H. L. Copp J Urol 2018;199:552-557.
    J Urol. 2018;200:205-206.
    PubMed     Text format    
    
    
28. BHINDI B, Wallis CJD
    Editorial Comment.
    J Urol. 2018;200:125.
    PubMed     Text format    
    
    
29. AMINSHARIFI A, Simon R, Polascik TJ, Robertson CN, et al
    Evaluation and active treatment versus active surveillance of localized prostate cancer in renal transplant patients in the era of low and very low risk prostate cancer.
    J Urol. 2019 Mar 5:101097JU0000000000000207. doi: 10.1097/JU.0000000000000207.
    PubMed     Text format     Abstract available
    
    
30. STONE NN, Crawford ED, Skouteris VM, Arangua P, et al
    The ratio of the number of biopsy specimens to prostate volume (biopsy density) > 1.5 improves the prostate cancer detection rate in men undergoing transperineal biopsy of the prostate.
    J Urol. 2019 Mar 5:101097JU0000000000000204. doi: 10.1097/JU.0000000000000204.
    PubMed     Text format     Abstract available
    
    
31. STEFANOVA V, Buckley R, Flax S, Spevack L, et al
    Transperineal prostate biopsies under local anesthetic: Experience with 1287 patients Prostate cancer detection rate, complications and patient tolerability.
    J Urol. 2019 Feb 8:101097JU0000000000000156. doi: 10.1097/JU.0000000000000156.
    PubMed     Text format     Abstract available
    
    
32. TAN N, Bavadian N, Calais J, Oyoyo U, et al
    Imaging of PSMA-targeted Radiotracers for the Detection of Prostate Cancer Biochemical Recurrence After Definitive Therapy: A Systematic Review and Meta-analysis.
    J Urol. 2019 Feb 25:101097JU0000000000000198. doi: 10.1097/JU.0000000000000198.
    PubMed     Text format     Abstract available
    
    
33. SIVARAMAN A, Kim EH, Andriole GL
    Editorial Comment.
    J Urol. 2019;201:112.
    PubMed     Text format    
    
    
34. PIERRARD V, Lebdai S, Kleinclauss F, Azzouzi AR, et al
    Radical Prostatectomy after Vascular Targeted Photodynamic Therapy with Padeliporfin: Feasibility, and Early and Intermediate Results.
    J Urol. 2019;201:315-321.
    PubMed     Text format     Abstract available
    
    
35. GORDETSKY JB, Rais-Bahrami S
    Editorial Comment.
    J Urol. 2018;200:112-113.
    PubMed     Text format    
    
    

    
    PLoS Genet

36. WILK G, Braun R
    regQTLs: Single nucleotide polymorphisms that modulate microRNA regulation of gene expression in tumors.
    PLoS Genet. 2018;14:e1007837.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

37. KANNAN A, Kirkman M, Ruseckaite R, Evans SM, et al
    Prostate cancer awareness, case-finding, and early diagnosis: Interviews with undiagnosed men in Australia.
    PLoS One. 2019;14:e0211539.
    PubMed     Text format     Abstract available
    
    

    
    Prostate

38. OJALILL M, Rappu P, Siljamaki E, Taimen P, et al
    The composition of prostate core matrisome in vivo and in vitro unveiled by mass spectrometric analysis.
    Prostate. 2018;78:583-594.
    PubMed     Text format     Abstract available
    
    
39. FURRER MA, Vilaseca A, Corradi RB, Boxler S, et al
    Repeat prostate biopsies prior to radical prostatectomy do not impact erectile function recovery and mid- to long-term continence.
    Prostate. 2018;78:631-636.
    PubMed     Text format     Abstract available
    
    
40. WANG X, Qi M, Zhang J, Sun X, et al
    Differential response to neoadjuvant hormonal therapy in prostate cancer: Predictive morphological parameters and molecular markers.
    Prostate. 2019 Mar 2. doi: 10.1002/pros.23777.
    PubMed     Text format     Abstract available
    
    
41. THOMAS-JARDIN SE, Kanchwala MS, Jacob J, Merchant S, et al
    Identification of an IL-1-induced gene expression pattern in AR(+) PCa cells that mimics the molecular phenotype of AR(-) PCa cells.
    Prostate. 2018;78:595-606.
    PubMed     Text format     Abstract available
    
    

    
    Radiology

42. SCIALPI M, Bianconi F, Cantisani V, Palumbo B, et al
    Radiomic Machine Learning: Is It Really a Useful Method for the Characterization of Prostate Cancer?
    Radiology. 2019 Mar 5:182940. doi: 10.1148/radiol.2019182940.
    PubMed     Text format    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: